2846 results about "Diabetes mellitus" patented technology

The invention relates to chemical compounds useful as inhibitors of class II phosphoinositide 3- kinase (PI3K) signalling. The invention further relates to the medical use of inhibitors of class II phosphoinositide 3-kinase (PI3K) signalling in the treatment of medical conditions associated with defective and / or pathologic class II phosphoinositide 3-kinase (PI3K) signaling, such as stroke, a cardiovascular disease related to endothelial cell dysfunction, cancer, cancer metastasis, myopathy and diabetes.

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).

The present invention is in the field of pharmaceutical chemistry, and relates to a compound containing a multi-fused ring structure, specifically to a compound of formula (I), a stereoisomer or pharmaceutically acceptable salt thereof, a preparation method therefor, or a pharmaceutical composition thereof, and a use thereof in the preparation of a drug for treating diabetes or obesity-related diseases.

The invention provides a tetrahydropyridinopyrazole derivative and application thereof in medicine, and particularly relates to a compound shown in a general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic of the compound, and an intermediate and a preparation method of the tetrahydropyridinopyrazole derivative. The invention also relates to application in preparation of related medicines for treating diabetes mellitus. # imgabs0 #

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The invention discloses a low-trigger-potential electrochemical luminescence enzyme biosensor for detecting glucose and a construction method and application thereof, the sensor comprises a three-electrode system formed by a working electrode, a reference electrode and a counter electrode, and a liquid to be detected contains luminol; the working electrode is a VMSF modified electrode of confined gold-palladium nanoparticles and is obtained by covalently immobilizing glucose oxidase. Luminol and glucose oxidase are respectively used as an electrochemical luminescence signal molecule and a specific recognition element; by combining the efficient and specific catalytic activity of natural enzyme, the efficient catalytic activity of gold-palladium nanoparticles on luminol electrochemical luminescence and the anti-pollution capacity of a vertical ordered mesoporous silica film, the low-trigger-potential electrochemical luminescence enzyme biosensor without an exogenous co-reactant is constructed; the method has the characteristics of high sensitivity, wide detection linear range and low detection limit, and has great application potential in constructing a portable glucose sensor for diagnosing and monitoring diabetes mellitus.

The invention discloses an effect evaluation method for a non-dialysis diabetic kidney disease, which comprises the following steps: monitoring the change trend of data by collecting renal function related data of a patient, and generating a basic data set; a dynamic nonlinear weighted regression algorithm is adopted to analyze the multi-dimensional renal function data, data weights are dynamically adjusted, and influence weights of different time periods are distributed according to the change mode of the illness state; the data influence is adjusted in real time through a time correlation mechanism, and a disease assessment curve is generated; according to the method, historical data and real-time data are combined, a patient condition trend line and a prediction result are generated, personalized treatment feedback is output, and intervention suggestions are provided for clinicians based on long-term prognosis prediction. The method is suitable for disease monitoring and treatment feedback of patients with non-dialysis diabetic kidney diseases.

The invention relates to a plant lactobacillus JN9, a preparation, a probiotic composition and application thereof. According to the application, a new plant lactobacillus JN9 strain is obtained through screening, and the preservation number of the new plant lactobacillus JN9 strain is CCTCC (China Center for Type Culture Collection) NO: M 20241647. Through basic characteristic analysis (growth curve, acid resistance, cholate resistance and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolysis capability, toxin production capability, cytotoxicity and biogenic amine production capability), adhesiveness evaluation, GABA production evaluation and alcohol tolerance and acetaldehyde dehydrogenase production capability evaluation of the strain, the strain is found to be a safe strain; and the GABA has excellent GABA production performance, high alcohol tolerance and high acetaldehyde dehydrogenase activity. The composition can be applied to products for improving mood, such as relieving pressure, resisting depression, improving body sleep quality, reducing blood pressure, resisting diabetes, resisting cancer, resisting oxidation, resisting inflammation, resisting microorganisms, resisting allergy, enhancing alcohol tolerance in drinking, relieving discomfort after drinking and the like.

The invention discloses a gestational diabetes auxiliary analysis system and method based on placenta ultrasonic textures, and the system comprises a multi-modal database which is used for storing placenta two-dimensional ultrasonic image data and clinical comprehensive data; the preprocessing module is used for screening the clinical comprehensive data and carrying out standardization processing and labeling on the image data; the image feature extraction module is used for constructing an image segmentation model based on a CNN network, performing image processing on the input placenta two-dimensional ultrasonic image through the image segmentation model, and obtaining an image feature data set; the risk prediction module is used for constructing a GDM risk prediction model; and the judgment module is used for carrying out risk classification on the GDM risk of the current pregnant woman by utilizing the image segmentation model and the GDM risk prediction model. By introducing a deep learning technology, intelligent analysis is performed on placenta ultrasonic images, clinical comprehensive data and other multi-modal data, and a reliable tool is provided for auxiliary analysis of gestational diabetes mellitus.

Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.

Provided in the present invention are a tetrahydropyridopyrazole derivative and use thereof in medicine. Specifically provided is a compound as shown in general formula (I) or a racemate, stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a preparation method therefor, and use thereof in the preparation of a related drug for treating diabetes or obesity.

The present disclosure provides a class of compounds represented by formula (I '), or tautomers, stereoisomers or pharmaceutically acceptable salts thereof. The compound disclosed by the invention has a relatively strong agonistic effect on GLP-1R, can be used for treating diseases such as diabetes mellitus, metabolism-related fatty liver diseases, Alzheimer's disease and the like or has an effect of reducing weight. # imgabs0 #

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and / or prevention of diabetes.

To provide formulations for treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease.SOLUTION: The invention provides a chemical formulation for use in a method of treating a disease, the method comprising: inserting a delivery catheter into a vascular lumen adjacent to nerves, where the vascular lumen includes a pulmonary artery; infusing the chemical formulation into the vascular lumen through the delivery catheter, where the amount of the chemical formulation is an amount effective to injure or damage the nerves and provide benefits in alleviating the symptoms of the disease; and withdrawing the delivery catheter from the blood vessel. The chemical formulation is at least one of 10-100 wt.% of ethanol, and 1-100 wt.% of acetic acid. The disease includes pulmonary arterial hypertension.SELECTED DRAWING: None

The invention relates to the technical field of artificial intelligence, and discloses a traditional Chinese medicine diabetes dry eye treatment difference evaluation system and method based on artificial intelligence, and the system comprises a four-diagnosis integrated module, a syndrome modeling module, an intelligent decision module, a curative effect feedback module, a knowledge base management module and a self-adaptive learning module. Multi-mode traditional Chinese medicine four-diagnosis data of tongue condition, pulse condition and eye diagnosis and modern physiological parameters of metabolic indexes are fused, a deep learning method is adopted for standardization processing, the problem that traditional Chinese medicine syndrome differentiation depends on subjective experience is solved, traditional Chinese medicine syndrome feature extraction of diabetes dry eye has objectivity and quantifiability, and the traditional Chinese medicine syndrome feature extraction efficiency is improved. The comprehensiveness and the accuracy of the diagnosis basis are improved; and the curative effect feedback module compares a prediction result with revival curative effect data in real time, and the knowledge base management module is linked to carry out case feature matching and strategy optimization, so that continuous optimization and long-term reliability of the treatment decision model are ensured.

Disclosed are naphthyl compounds comprising either a ureido piperidine-1 -carboxamide or a ureido piperidine-1 -carboxylate moiety, compositions thereof, and methods of use thereof, for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport, such as phenylketonuria, hyperphenylalaninemia, diabetes and chronic kidney disease.

The invention relates to a pressure injury intelligent prediction and prevention method and system, and the method comprises the steps: determining target comprehensive monitoring data of a patient, the target comprehensive monitoring data comprising microenvironment data indicating body surface temperature, body surface humidity and pressure on a pressed part, and individual feature data indicating the gender, age and whether the patient suffers from diabetes; based on the comprehensive monitoring data, a machine learning model based on ensemble learning is adopted for analysis to obtain a risk score, the machine learning model comprises a plurality of basic learners, and each basic learner performs performance evaluation in advance based on a method of combining cross validation and feature importance evaluation; corresponding weights are distributed according to scores of the performance evaluation indexes, weighted average combination is carried out based on prediction results of all the basic learners, and a prediction result of the integrated model can be obtained; and performing quantitative evaluation on the pressure injury occurrence risk of the pressed part of the patient based on the risk score, and generating a risk report.

The invention discloses a gestational diabetes risk intelligent prediction method based on multi-modal data fusion, and particularly relates to the technical field of data processing, and the method comprises the steps: S1, setting a prediction window, S2, obtaining risk detection data, S3, constructing a multi-modal time sequence matrix, S4, carrying out risk analysis, S5, constructing a gestational risk change curve, and S6, carrying out visual display. According to the method, detection is carried out through physiological risk indexes and biochemical risk indexes, multi-modal time sequence matrix construction is carried out based on risk detection data, the data acquisition accuracy is met, a matrix structure of time periods and multiple indexes is formed, correlation analysis is carried out on pregnancy risks and detection time periods, and a pregnancy risk change curve is constructed from the correlation analysis; the dynamic evolution of the risk along with pregnancy is visually displayed, the risk occurrence time can be accurately positioned through inflection point detection, key detection of the risk occurrence time is facilitated, and a structured foundation is laid for the follow-up risk change trend and fluctuation amplitude.

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.

The invention relates to the technical field of intelligent health monitoring, in particular to a physiological signal driven diabetes mellitus metabolism risk modeling analysis system which comprises a variable sorting module, an electrocardio shearing module, a distribution edge forming module, a risk modeling module and a regulation and control deconstruction module. According to the method, the fluctuation response time difference between the skin temperature and the blood oxygen signal is obtained, distribution density analysis is conducted on the time difference, the samples are divided into response difference groups, and layered recognition of the signal time dynamic characteristics is achieved; a peak-valley amplitude sequence in the electrocardiogram periodic signal is further extracted, an amplitude withdrawing ratio is calculated, a key turning point is identified according to a threshold value, and the corresponding periodic signal is divided into different electrocardiogram segments, so that the micro electrocardiogram fluctuation response is effectively positioned; on the basis, according to the time index, the asynchronous distribution section of the skin temperature and the blood oxygen is backtracked, a cross boundary graph between the asynchronous signals is constructed, and the asymmetric response mode of skin temperature and blood oxygen changes can be analyzed in a refined mode.

The invention relates to the technical field of occupational health management, and particularly discloses a method for health assessment and management of occupational crowds, which comprises the steps of S1, health management service planning, S2, health management service principles, S3, health management service crowd classification, S4, health management service modes and S5, health management service contents. S6, building a health management information system; and S7, evaluating and feeding back effects. Through health monitoring, early intervention and continuous management, occurrence and development of chronic diseases, cardiovascular diseases and diabetes mellitus are effectively prevented and delayed, the health level of the whole employees is improved, after a health management project is implemented, the health conditions of the employees are improved, the conditions of false illness and absence caused by the diseases are reduced, and the safety of the employees is improved. The system can be used for preventing and controlling diseases, particularly preventing and controlling chronic diseases, the frequency of absence due to diseases is remarkably reduced, and resource waste caused by excessive medical treatment, repeated physical examination and the like is reduced through precise health assessment and personalized intervention measures.

The invention relates to a diabetes mellitus question-answering method, system and device based on a knowledge graph and a medium, and belongs to the technical field of medical intelligent question-answering. The diabetes mellitus question-answering method based on the knowledge graph analyzes a question sentence of a user based on a pre-trained intention classification model so as to identify a user intention; analyzing the user question based on a pre-trained named entity recognition model to recognize a question entity; performing dynamic query on the constructed diabetes knowledge graph based on the user intention and the question entity to obtain a knowledge graph query result; encoding the user question by adopting a retrieval enhancement generation model, and performing semantic retrieval on the constructed diabetes semantic retrieval library based on the encoded user question to obtain related knowledge corresponding to the user question; and the knowledge graph query result and related knowledge are input into the constructed large language model to obtain the diabetes mellitus question and answer, so that the accuracy and specialty of the answer are improved.

Embodiments of the present invention are directed to the treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease by delivering of an effective amount of formulations at desired temperature to target tissue. The formulations include gases, vapors, liquids, solutions, emulsions and suspensions of one or more ingredients. The temperature may enhance safety and efficacy of the formulations for the treatments. The amounts of the formulation and / or energy are effective to injury or damage the tissues to have a benefit of symptom relive.

The invention discloses an intelligent prediction system and method for gestational diabetes mellitus, and relates to the technical field of medical artificial intelligence, and the system comprises a collection module which is used for collecting gestational index data, carrying out the preprocessing of the index data, and extracting the features of the preprocessed data; the evaluation module is used for performing synchronism and rhythm analysis according to the extracted features, establishing a physiological cycle correlation model and evaluating the synchronism and disorder degree of the physiological rhythm; and the prediction module is used for constructing a risk prediction model according to the analysis result of the physiological cycle correlation model and predicting the physiological state risk level. According to the invention, the early recognition rate of gestational diabetes mellitus is obviously improved, the disease incidence and complication risk are reduced, the consumption of medical resources is reduced, and the method has important clinical application value and social benefit. And parameter optimization and model adjustment can be performed according to different crowd characteristics, so that powerful support is provided for personalized medical treatment and accurate prevention.

Provided are a compound represented by formula (I'), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof. The compound represented by formula (I') has a strong agonistic effect on GLP-1R, and can treat diseases such as diabetes, metabolic-associated fatty liver diseases, and Alzheimer's disease, or has a weight loss effect.

The invention relates to a new non-invasive quantitative test making it possible to detect liver fibrosis in type-2diabetes using non-invasive tests that are sex-specific.

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

The invention relates to the technical field of biological medicine, in particular to a dynamic fermentation tank control system for producing a diabetes intestinal microecological regulating preparation. The system comprises a fermentation tank sensing feedback control network establishment module, a fermentation tank growth earlier-stage nutrition supply control module, a fermentation tank growth later-stage adjustment control module and a fermentation tank metabolism process environmental condition control module, and can generate an embedded sensing feedback control network by installing a sensor and being connected with a central feedback control system. The sugar source supply quantity, the nitrogen source supply quantity, the temperature, the pH value, the dissolved oxygen concentration and the oxygen and carbon dioxide gas proportional flow corresponding to the fermentation tank are synchronously monitored in real time, so that supply cooperative dynamic control and fermentation growth cooperative dynamic control are carried out, and meanwhile, metabolism environment condition cooperative dynamic control is carried out; therefore, the cooperative control work of the microbial growth environment conditions is executed. By optimizing environment control in the fermentation process, efficient production of the intestinal microecology regulating preparation can be achieved.